Takeda Pharmaceutical Company Limited (TSE:4502) is a Japanese multinational pharmaceutical company founded in 1781, making it one of the oldest pharmaceutical companies in the world. Originally established as a traditional medicine shop in Osaka, Takeda has evolved into a global biopharmaceutical leader headquartered in Tokyo. The company operates across major markets including Japan, the United States, Europe, and other international regions, focusing on research, development, manufacturing, and marketing of innovative pharmaceutical products. Following its transformative $62 billion acquisition of Shire plc in 2019, Takeda has positioned itself as a leading player in specialized therapeutic areas including gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience.
JPY 5,946.00
+1.69%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenJPY 5,992.00
From 52W high−0.37%
Volume6.52M
Market capJPY 9.39T
P/E (TTM)52.1x
P/S (TTM)2.0x
Div yield3.36%
Key dataSep 18, 2026
Open
JPY 5,992.00
From 52W high
−0.37%
Volume
6.52M
Market cap
JPY 9.39T
ValuationView details →
P/E (Fwd)
40.7x
EV/EBITDA
11.0x
P/E (TTM)
52.1x
RSI (14)
63.9
MomentumView details →
1D Return
+1.69%
YTD Return
+23.43%
SummaryUpdated Jun 1, 2026
Latest newsMore news →
Takeda's QDENGA, a live-attenuated tetravalent dengue vaccine, is set to become India's first approved dengue vaccine, with private-market availability expected in the first half of 2027.2d agoDr Reddy's Laboratories signed a distribution agreement with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India.3d agoTakeda Pharmaceutical received manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare for Elahere, an antibody-drug conjugate for FRα-positive platinum-resistant recurrent ovarian cancer, the first such ADC approved in Japan for this indication.4d ago